<DOC>
	<DOCNO>NCT01378975</DOCNO>
	<brief_summary>This open-label , single-arm , multicenter study evaluate efficacy safety participant metastatic melanoma develop brain metastasis . Participants may may receive prior systemic treatment metastatic melanoma [ except treatment v-raf murine sarcoma viral oncogene homolog B ( BRAF ) mitogen-activated protein kinase ( MEK ) inhibitor ] . Participants receive oral dos 960 mg vemurafenib twice daily disease progression , unacceptable toxicity consent withdrawal .</brief_summary>
	<brief_title>A Study Vemurafenib Metastatic Melanoma Participants With Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Adult participant , &gt; /= 18 year age Histologically confirm metastatic melanoma ( Stage IV , American Joint Committee Cancer ) BRAF V600 mutation ( cobas 4800 BRAF V600 Mutation Test ) Measurable brain metastasis , define lesion accurately measure least one dimension ( long diameter record ) ≥0.5 cm brain MRI contrast , treat untreated Participants may may receive prior systemic therapy metastatic melanoma either ) receive prior treatment brain metastasis b ) receive prior treatment brain metastasis progress Participants may may symptoms related brain metastasis Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Participants must recover side effect recent systemic local treatment metastatic melanoma Increasing corticosteroid dose 7 day prior first dose study drug Leptomeningeal involvement participant prior treatment brain metastasis Previous malignancy require active treatment within past 2 year , except treat control basal squamous cell carcinoma skin , carcinoma insitu cervix Concurrent administration anticancer therapy administer study Treatment cytotoxic , investigational drug target therapy 4 week prior first dose study drug . Radiation therapy ≤1 week prior first administration vemurafenib ; stereotactic radiotherapy ≤1 day prior prior first administration vemurafenib Prior treatment BRAF MEK inhibitor Clinically significant cardiovascular disease event within 6 month prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>